Duke logo

Alliance A081105 (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare the standard treatment with standard treatment plus the study drug erlotinib to see which one is better.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer

Who Can Participate in the Study?

Adults with non-small cell lung cancer who:
- Have completely resected non-squamous non-small cell lung cancer
- Have no history of cornea abnormalities
- Are not pregnant or nursing

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be randomized (like the flip of a coin) and get either:
-- Group 1: The study drug erlotinib for up to 2 years
-- Group 2: Observation; will not get erlotinib but will be followed by their study doctor
-- Get a CT scan and clinic visits every 6 months for the first 4 years and then yearly for the following 6 years for up to 10 years from the start of the study

Study Details

Full Title
Alliance A081105: Randomized Study of Erlotinib versus Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00057973
NCT:NCT02193282
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698